Preferred Label : Anti-CD25-IL-2 Monoclonal Antibody AU-007;
NCIt definition : A human immunoglobulin (Ig) G1 monoclonal antibody directed against the CD25 subunit-interacting
domain of the cytokine interleukin-2 (IL-2; IL2), with potential immunomodulatory
activity. Upon administration, anti-CD25-IL2 monoclonal antibody AU-007 targets, binds
to and blocks the CD25 subunit-interacting domain of IL-2, thereby blocking the binding
of IL-2 to the CD25 subunit (IL-2 receptor subunit alpha; IL-2Ralpha) of the human
trimeric IL-2 receptor (IL-2R) expressed on the surface of regulatory T-lymphocytes
(Tregs), thereby inhibiting IL-2Ralpha-mediated Tregs activation. This may prevent
Treg-mediated immunosuppression. As the ability of IL-2 to bind to dimeric CD122 (IL-2Rbeta)/CD132
receptor is preserved, AU-007 promotes immune effector activation by IL-2 via IL-2-mediated
signaling through the dimeric IL-2R. This may active an anti-tumor immune response
against tumor cells through activation of T-lymphocytes, natural killer (NK) cells,
and NK T-cells, thereby killing cancer cells. In addition, by blocking the binding
of IL-2 to CD25 expressed on vascular endothelium and smooth muscle cells and subsequent
activation, exacerbation of vascular leak syndrome (VLS) is prevented. IL-2 binds
to the IL-2R dimeric receptor expressed on CD8 T effector cells, memory T cells, NK
cells and NKT cells and is composed of CD122 and CD132. The IL-2R trimeric receptor
expressed on Tregs and vascular endothelium is composed of CD25, CD122 and CD132.;
Molecule name : AU 007; AU-007;
NCI Metathesaurus CUI : CL1792022;
Origin ID : C187110;
UMLS CUI : C5706357;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
